Dolutegravir/Lamivudine Provide HIV Suppression Through 3-Year TANGO Findings

Video

The combination therapy's non-inferior efficacy to heavier TAF regimens may indicate a greater embrace of 2-drug regimens for people living with HIV.

New 3-year findings presented at IDWeek 2021 show combination therapy dolutegravir/lamivudine (Dovato) was associated with high efficacy non-inferior to 3- or 4-drug tenofovir alafenamide (TAF)-based regimens for HIV viral suppression.

The 144-week findings from ViiV Healthcare’s TANGO trial support long-term efficacy of switching people living with HIV from a TAF regimen to the 2-dose option.

Presented by Olayemi Osiyemi, MD, President of Triple O Research Institute in West Palm Beach, the TANGO trial showed non-inferior efficacy of dolutegravir/lamivudine to TAF-based 3- or 4-drug regimens, with no confirmed virologic withdrawals in treated participants and a favorable tolerability and safety profile of patients receiving the 2-drug regimen.

In an interview with Contagion during IDWeek, Osiyemi reviewed the trial data, and discussed the value of interpreting long-term efficacy and safety for HIV virologic suppression with regimens that require fewer drugs for patients.

“I guess you have to have the right marriage—the right 2 drugs to make it work,” Osiyemi said. “If we can use the fewest number of drugs, we can eliminate long-term toxicity and drug costs.”

Newsletter

Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

Recent Videos
© 2025 MJH Life Sciences

All rights reserved.